Literature DB >> 17412456

Synthesis and cytotoxicity studies of new dimethylamino-functionalised and aryl-substituted titanocene anti-cancer agents.

Clara Pampillón1, James Claffey, Katja Strohfeldt, Matthias Tacke.   

Abstract

From the carbolithiation of 6-N,N-dimethylamino fulvene (3a) and different lithiated aryl species [p-N,N-dimethylanilinyl lithium, p-anisyl lithium and 4-lithio-benzo[1.3]dioxole (2a-c)], the corresponding lithium cyclopentadienide intermediates 4a-c were formed. These three lithiated intermediates underwent a transmetallation reaction with TiCl4 resulting in dimethylamino-functionalised and aryl-substituted titanocenes 5a-c. When these titanocenes were tested against LLC-PK cells, the IC50 values obtained were of 54, 45 and 26microM for titanocenes 5a, b and c, respectively. The most cytotoxic titanocene in this paper, 5c is approximately 10 times less cytotoxic than cis-platin, which showed an IC50 value of 3.3microM, when tested on the LLC-PK cell line, but approximately 100 times better than titanocene dichloride.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17412456     DOI: 10.1016/j.ejmech.2007.02.011

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  3 in total

1.  Synthesis and cytotoxicity studies of steroid-functionalized titanocenes as potential anticancer drugs: sex steroids as potential vectors for titanocenes.

Authors:  Li Ming Gao; José L Vera; Jaime Matta; Enrique Meléndez
Journal:  J Biol Inorg Chem       Date:  2010-03-28       Impact factor: 3.358

2.  Anticancer activity and mode of action of titanocene C.

Authors:  Ulrike Olszewski; James Claffey; Megan Hogan; Matthias Tacke; Robert Zeillinger; Patrick J Bednarski; Gerhard Hamilton
Journal:  Invest New Drugs       Date:  2010-02-17       Impact factor: 3.850

3.  Ability of Group IVB metallocene polyethers containing dienestrol to arrest the growth of selected cancer cell lines.

Authors:  Michael R Roner; Charles E Carraher; Kimberly Shahi; Yuki Ashida; Girish Barot
Journal:  BMC Cancer       Date:  2009-10-07       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.